Ambrilia Biopharma Inc.: Annual and Special Meeting of Shareholders

MONTREAL, QUEBEC, Jun 30 (MARKET WIRE) --
Ambrilia Biopharma Inc. (TSX: AMB) announced today that it will hold its
Annual and Special Meeting of Shareholders on Tuesday, August 4, 2009, at
10:30 am ET at Bourse de Montreal, La Tour de la Bourse, 800 Victoria
Square, 4th Floor, Montreal, Quebec, H4Z 1A9.

Mr. Frederic Porte, Chairman of the Board of Directors, will lead the
formal part of the meeting. Dr. Philippe Calais, President and CEO, will
present the latest highlights of the Company's activities. After the
presentation, Dr. Calais will moderate a Q&A session.

About Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc. (TSX: AMB) is a biotechnology company focused on
the discovery and development of novel treatments for viral diseases and
cancer. The Company's strategy aims to capitalize on its broad portfolio
and original expertise in virology. Ambrilia's product portfolio is
comprised of oncology and antiviral assets, including two new
formulations of existing peptides for cancer treatment, a therapeutic
peptide for prostate cancer, a targeted delivery technology for cancer,
an HIV protease inhibitor program as well as HIV integrase and entry
inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds.
Ambrilia's head office, research and development and manufacturing
facilities are located in Montreal. For more information, please visit
the Company's web site: www.ambrilia.com.

Ambrilia's forward looking statements

This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. There is a risk
that expectations and forward looking statements will not prove to be
accurate. Readers are cautioned not to place undue reliance on these
forward-looking statements as they involve risks and uncertainties, which
could make actual results differ materially from those projected herein
and depend on a number of factors including, but not limited to, changing
market conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process, establishment
of corporate alliances and other risks detailed from time to time in the
Company's filings. We refer you to the Risk Factors section of the
Company's annual information form which contains a more exhaustive
analysis of the risks and uncertainties that are generally connected to
the business of the Company. Such statements are also based on various
assumptions, including the successful and timely completion of clinical
studies on Ambrilia's products demonstrating efficacy and safety for
human use, their successful commercialization within the forecasted
timelines and the attainment of the forecasted milestone payments and
other revenues. Failure to complete a strategic or financial transaction
as a result of the review of strategic alternatives could have a material
adverse effect on Ambrilia. While Ambrilia anticipates that subsequent
events and developments may cause Ambrilia's views to change, Ambrilia
specifically disclaims any obligation to update these forward looking
statements, unless obligated to do so by applicable securities laws.

Contacts:
Ambrilia Biopharma Inc.
Dr. Philippe Calais, Ph.D., Pharm.
President & CEO
514-751-2003 ext 230
pcalais@ambrilia.com
www.ambrilia.com

Copyright 2009, Market Wire, All rights reserved.

-0-